Zacks Investment Research lowered shares of Halyard Health Inc. (NYSE:HYH) from a buy rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “

A number of other research firms also recently commented on HYH. Deutsche Bank AG upped their price objective on shares of Halyard Health from $36.00 to $41.00 and gave the company a buy rating in a research note on Wednesday, August 10th. Stifel Nicolaus upped their price objective on shares of Halyard Health from $37.00 to $38.00 and gave the company a buy rating in a research note on Thursday, August 4th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Halyard Health has an average rating of Buy and an average target price of $38.00.

Halyard Health (NYSE:HYH) traded down 0.669% on Tuesday, hitting $35.948. 60,136 shares of the stock traded hands. The firm’s 50-day moving average price is $34.19 and its 200-day moving average price is $33.75. Halyard Health has a 12-month low of $22.76 and a 12-month high of $37.31. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of 38.283 and a beta of 1.77.

Halyard Health (NYSE:HYH) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $0.48 EPS for the quarter, beating the Zacks’ consensus estimate of $0.39 by $0.09. Halyard Health had a net margin of 2.80% and a return on equity of 8.63%. The company earned $398 million during the quarter, compared to the consensus estimate of $387.64 million. During the same quarter in the prior year, the company posted $0.52 EPS. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts anticipate that Halyard Health will post $1.91 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Paradice Investment Management LLC increased its stake in Halyard Health by 12.2% in the second quarter. Paradice Investment Management LLC now owns 1,357,237 shares of the company’s stock worth $44,137,000 after buying an additional 147,566 shares during the period. Nuveen Asset Management LLC increased its stake in Halyard Health by 22.2% in the first quarter. Nuveen Asset Management LLC now owns 85,044 shares of the company’s stock worth $2,443,000 after buying an additional 15,467 shares during the period. Emerald Acquisition Ltd. acquired a new stake in Halyard Health during the second quarter worth about $4,905,000. Victory Capital Management Inc. increased its stake in Halyard Health by 46.3% in the second quarter. Victory Capital Management Inc. now owns 1,132,400 shares of the company’s stock worth $36,826,000 after buying an additional 358,150 shares during the period. Finally, Springbok Capital Management LLC increased its stake in Halyard Health by 151.9% in the first quarter. Springbok Capital Management LLC now owns 6,800 shares of the company’s stock worth $195,000 after buying an additional 4,100 shares during the period. 85.38% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This news story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States & international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/23/halyard-health-inc-hyh-lowered-to-hold-at-zacks-investment-research.html.

About Halyard Health

Halyard Health, Inc seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company operates through two segments: Surgical and Infection Prevention (S&IP) and Medical Devices. Its S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections.

5 Day Chart for NYSE:HYH

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.